(RTTNews) – Basilea Pharmaceutica Ltd introduced that gross sales of the antifungal Cresemba (isavuconazole) by its license accomplice Pfizer in Europe have exceeded the edge that triggered a milestone fee of $25 million to Basilea.
The license settlement between Basilea and Pfizer for Cresemba covers Europe (excluding the Nordic international locations) in addition to 16 international locations within the Asia Pacific area and China.
In response to the most recent obtainable market information, whole international in-market gross sales of Cresemba amounted to $489 million within the 12 months between April 2023 and March 2024, a 24 p.c progress year-on-year.
Isavuconazole is an intravenous and oral azole antifungal, commercialized beneath the commerce title Cresemba. Basilea has entered into a number of license and distribution agreements for isavuconazole overlaying roughly 115 international locations. Within the 27 European Union member states, in addition to in Iceland, Liechtenstein and Norway, isavuconazole is accredited for sufferers aged from 1 yr of age and older for the remedy of invasive aspergillosis and for the remedy of mucormycosis in sufferers for whom amphotericin B is inappropriate.
Isavuconazole can also be accredited in america and a number of other extra international locations in Europe and past, together with the U.Ok., China and Japan. It has orphan drug designation within the US, Europe and Australia for its accredited indications.
The views and opinions expressed herein are the views and opinions of the creator and don’t essentially replicate these of Nasdaq, Inc.
